Multiplex Base Editing in Human Hematopoietic Stem and Progenitor Cells (HSPCs) Enables Efficient Removal of Multiple Surface Antigens in Acute Myeloid Leukemia (AML) Immunotherapy
We have built a proprietary technology platform
The key components of the Vor Bio platform are:
Stem cell biology and
We have built an extensive understanding of the biology of Hematopoietic Stem Cells (HSCs) to enable our eHSCs to retain their cellular viability and functionality during manipulation. In addition, we have built process development expertise centered around HSCs, enabling us to process these cells quickly, precisely, reproducibly, and efficiently for patients. We have invested in internal in-house clinical GMP manufacturing capabilities and facilities that allow us to leverage our expertise and to maintain strategic control over the manufacturing process
engineering to HSCs
Recent developments in genome engineering allow permanent changes to DNA in cells and all their progeny. We have assembled a team with extensive experience in applying genome engineering technologies to HSCs, which display distinct DNA repair mechanisms compared to many other cell types. We possess expertise in a variety of genome engineering technologies including CRISPR-Cas9, CRISPR analog enzymes, and base editing, and we are capable of multiplex editing using a variety of techniques.
Unlocking the potential of
We believe our eHSCs are a solution to the lack of tumor-specific targets and enable selective cancer targeting. Our solution allows for treatment with potent agents, such as CAR-T therapies, whose utility and applicability have previously been limited, in part, by on-target toxicity. We are designing and developing targeted therapies that are optimized for use with our eHSCs in the post-HSCT setting.
Our goal is to replace the patient’s HSCs with next-generation, treatment-resistant eHSCs that unlock the potential of highly potent targeted therapies by leveraging our platform and expertise.
for Drug Development
Target cancer antigens to kill cancer cells
Few unique cancer antigens, so drugs kill both cancer and healthy cells through on-target toxicity
Vor Bio Paradigm:
Engineered HSCs (eHSCs)
Remove target expression on healthy cells so that killing is cancer-specific
Knock Out of CD123 or CLL-1 by CRISPR-Cas9 Editing From Human Hematopoietic Stem Cell Transplantations Provide New Possibilities for Increasing Therapeutic Index and Safety for AML Treatment